Molecular diagnostics

Laboratory Developed Tests Global Market Report 2022: Increasing Demand for Development of Personalized Medicine Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 23, 2023
Health, Biotechnology, Immunoassay, Segmental analysis (biology), Laboratory, Helmy Eltoukhy, Molecular diagnostics, Monkeypox virus, Colorectal cancer, Nutrition, LDT, Diagnosis, Breast cancer, Oncology, Patient, NHS England, DSM-IV codes, Quest Diagnostics, Genetics, Chapter Three, USD, Lung cancer, Laboratory developed test, Death, England, FDA, Growth, OPKO Health, Shield, Prevalence, Cancer, Infection, Ageing, Medical device, Pharmaceutical industry

The global laboratory developed tests market size is expected to reach USD 16.72 billion by 2030, expanding at a CAGR of 6.58% from 2023 to 2030.

Key Points: 
  • The global laboratory developed tests market size is expected to reach USD 16.72 billion by 2030, expanding at a CAGR of 6.58% from 2023 to 2030.
  • The growth of the industry is attributed to the increasing prevalence of chronic and genetic diseases, infectious & autoimmune diseases, and rising awareness among the population about healthy living.
  • The laboratory-developed tests (LDTs) are generated and utilized in the laboratories, and LDTs are released into the market without FDA approval or any other independent regulatory assessment.
  • Chapter 3 Laboratory Developed Tests Market Variables, Trends, & Scope
    Chapter 4 Laboratory Developed Tests Market - Segment Analysis, By Technology, 2018 - 2030 (USD Million)
    4.1 Laboratory Developed Tests Market: Technology Movement Analysis

BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test

Retrieved on: 
Wednesday, February 8, 2023
BD, Administration, Laboratory, CE, Molecular diagnostics, Hospital, SARS-CoV-2, United States Department of Health and Human Services, Virus, Diagnosis, PCR, NYSE, RSV, Urinary tract infection, RUO, Food, Health, Research, Biomedical Advanced Research and Development Authority, UDP, BDX, IVD, Becton, Season, EC, FDA, Infection, Becton, Dickinson and Company headquarters, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, Vaccine, Medical device

FRANKLIN LAKES, N.J., Feb. 8, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV) to help combat illness in the current and future respiratory virus seasons.

Key Points: 
  • The test helps eliminate the need for multiple tests or doctor visits and can help clinicians implement the right treatment plan quickly.
  • The co-testing approach also helps to increase testing capacity during the busy flu/RSV season and speed time to diagnosis.
  • The BD Respiratory Viral Panel assay for BD MAX™ System was CE marked under the IVD directive 98/79/EC in May of 2022.
  • The BD MAX™ open system allows customers to leverage research use only (RUO) assays and user-defined protocols (UDP) to address emerging needs quickly.

Laboratory Developed Tests Global Market Report 2022: Industry to Reach $16.72 Billion by 2030 at a 6.58% CAGR

Retrieved on: 
Wednesday, January 25, 2023
USD, Quest Diagnostics, Immunoassay, LDT, Monkeypox virus, Chapter Three, Diagnosis, Death, NHS England, Infection, Shield, OPKO Health, Lung cancer, Oncology, DSM-IV codes, FDA, Colorectal cancer, Growth, Cancer, Molecular diagnostics, Prevalence, Segmental analysis (biology), Ageing, Breast cancer, Genetics, England, Laboratory, Patient, Helmy Eltoukhy, Laboratory developed test, Nutrition, Medical device, Pharmaceutical industry

The global laboratory developed tests market size is expected to reach USD 16.72 billion by 2030, expanding at a CAGR of 6.58% from 2023 to 2030.

Key Points: 
  • The global laboratory developed tests market size is expected to reach USD 16.72 billion by 2030, expanding at a CAGR of 6.58% from 2023 to 2030.
  • The laboratory-developed tests (LDTs) are generated and utilized in the laboratories, and LDTs are released into the market without FDA approval or any other independent regulatory assessment.
  • LDTs are most typically employed in molecular diagnostics, which includes tests that target a variety of different chemicals in addition to genetics.
  • Chapter 3 Laboratory Developed Tests Market Variables, Trends, & Scope
    Chapter 4 Laboratory Developed Tests Market - Segment Analysis, By Technology, 2018 - 2030 (USD Million)
    4.1 Laboratory Developed Tests Market: Technology Movement Analysis

Global Molecular Diagnostics for Infectious Disease Market Report 2022 to 2026: Featuring Aureum Diagnostics, Aus Diagnostics, Beckman Coulter Diagnostics and Binx Health Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, January 16, 2023
Health, Infectious Diseases, Biometrics, Health Technology, Genetics, General Health, Biotechnology, Microbiology, Syndrome, Drug resistance, Molecular diagnostics, Infection, Diagnosis, Country, Genomics, COVID-19, Pharmaceutical industry

The "Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country.

Key Points: 
  • The "Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country.
  • With COVID-19 Impact & Forecasting/Analysis, and Executive Guides and Customization 2022-2026" report has been added to ResearchAndMarkets.com's offering.
  • The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth.
  • A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe.

Syndromic Multiplex Panels Global Market Report 2023: Market Enters a New Post Pandemic Growth Phase as New Entrants Jockey for Position in a New Diagnostic World - ResearchAndMarkets.com

Retrieved on: 
Monday, January 16, 2023
Health, Biotechnology, Home, Molecular diagnostics, Point, Infection, COVID, Multisystem inflammatory syndrome in children, Physician, Vaccine, Pharmaceutical industry

The COVID pandemic has ushered in a new world of infectious disease diagnostics.

Key Points: 
  • The COVID pandemic has ushered in a new world of infectious disease diagnostics.
  • Infectious disease Dx is changing and will change more in the future.
  • Find out all about it in this comprehensive report on Syndromic Multiplex Diagnostics.
  • In a special section, the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel based ordering of infectious disease tests.

Molecular Diagnostics at the Point of Care Market Report 2023: New Genotypes Creating New Markets - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Research, Managed Care, Medical Devices, Infectious Diseases, Hospitals, Science, COVID-19, Biotechnology, Medical Supplies, AIDS, Other Science, Health, Home, Molecular diagnostics, Point-of-care testing, COVID-19, Infection, Point, Country, Application, COVID-19 testing, Physician, Pharmaceutical industry

The "Molecular Diagnostics at the Point of Care: By Application, Technology, Place, Product and by Country, with COVID-19 PoC Breakout and Executive Guides" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Diagnostics at the Point of Care: By Application, Technology, Place, Product and by Country, with COVID-19 PoC Breakout and Executive Guides" report has been added to ResearchAndMarkets.com's offering.
  • The COVID-19 pandemic is ushering in a new world of point of care diagnostics.
  • Find out all about it in this comprehensive report on Molecular Diagnostics at the Point of Care.
  • The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success.

BD, CerTest Biotec Announce Emergency Use Authorization for Mpox Diagnostic Test

Retrieved on: 
Monday, January 9, 2023
TNA, Food, Emergency Use Authorization, Urinary tract infection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Molecular diagnostics, Research, World Health Organization's response to the COVID-19 pandemic, Becton, Disease, NYSE, Infection, EUA, Becton, Dickinson and Company headquarters, Health, FDA, BD, BDX, Vaccine, Diagnosis, PCR, Pharmaceutical industry, Computer data storage

FRANKLIN LAKES, N.J., Jan. 9, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and CerTest Biotec have announced Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a molecular polymerase chain reaction (PCR) assay for Mpox virus detection.

Key Points: 
  • The VIASURE Monkeypox Virus Real Time PCR Reagents for BD MAX System* is now available for BD MAX™ System users.
  • "The Mpox outbreak continues to be designated as a global health emergency — the World Health Organization's highest level of alert," said Nikos Pavlidis, vice president of Molecular Diagnostics at BD.
  • "We were able to quickly develop the VIASURE mpox molecular test by leveraging the BD MAX™ System's open system reagent suite," said Nelson Fernandes, managing director of CerTest Biotec.
  • As with all CerTest assays, the VIASURE Monkeypox Virus PCR Detection assay for the BD MAX™ System is offered in a lyophilized format.

QuidelOrtho Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022

Retrieved on: 
Friday, January 6, 2023
Medical Supplies, Health, Infectious Diseases, COVID-19, Pharmaceutical, Biotechnology, Interest, EST, Molecular diagnostics, Transfusion medicine, GAAP, COVID-19, PST, Point of care, Growth, Patient, Webcast, Conference, Point, Pharmaceutical industry

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary unaudited revenue results for the fourth quarter and full year ended January 1, 2023.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary unaudited revenue results for the fourth quarter and full year ended January 1, 2023.
  • The Company expects total revenues in the fourth quarter of 2022 to be in the range of $853 million to $868 million.
  • The Company expects total revenues in the full year of 2022 to be in the range of $4,038 million to $4,053 million.
  • Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PST / 5:00 p.m. EST to discuss the financial results.

Veterinary Reference Laboratory Global Market Report 2023: Rising Demand for Pet Insurance and Increasing Animal Health Expenditure Boosts Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, January 6, 2023
Biotechnology, Health, Other Natural Resources, Pets, Agriculture, Other Science, Natural Resources, Health Insurance, Consumer, Science, Veterinary, Cat, Horse, Region, Milk, Dairy, Molecular diagnostics, Parasitology, PETS, USD, Dog, Animal, Growth, Pathology, Bacteriology, Parasitism, ELISA, Companion, Hospital Insurance and Diagnostic Services Act, Incidence, PCR, Pet, Veterinary medicine, Virology, Livestock

The immunodiagnostic services segment is expected to account for the second-largest share of the veterinary reference laboratory market.

Key Points: 
  • The immunodiagnostic services segment is expected to account for the second-largest share of the veterinary reference laboratory market.
  • The clinical pathology segment is expected to grow with the highest CAGR of the veterinary reference laboratory market.
  • Based on animal type, the veterinary reference laboratory market for companion animal is segmented into dogs, cats, horses, and other companion animals.
  • In 2021, the market for dogs accounted for the largest share of the veterinary reference laboratory market for companion animals.

Syndromic Multiplex Diagnostic Global Market Report 2023: Syndromic Testing Presents New World for Diagnostics - ResearchAndMarkets.com

Retrieved on: 
Friday, January 6, 2023
Health, Biotechnology, COVID, Molecular diagnostics, Infection, COVID-19, Market analysis, Multisystem inflammatory syndrome in children, Syndromic testing, Panel, Home, Country, Physician, Point, Pharmaceutical industry, Sepsis, Syndrome

), by Country, with Market Analysis, Executive Guides and Customization" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • ), by Country, with Market Analysis, Executive Guides and Customization" report has been added to ResearchAndMarkets.com's offering.
  • The COVID pandemic is ushering in a new world of infectious disease diagnostics.
  • Find out all about it in this comprehensive report on Syndromic Multiplex Diagnostics.
  • In a special section, the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel-based ordering of infectious disease tests.